Opportunities and challenges following approval of resmetirom for MASH liver disease

Lazarus, Jeffrey V.; Ivancovsky Wajcman, Dana; Mark, Henry E.; Younossi, Zobair M.; Kopka, Christopher J.; Cohen, Nevin; Bansal, Meena B.; Betel, Michael; Brennan, Paul N.

doi:10.1038/s41591-024-02958-z

Cited by 4 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a pilot study is proposed to explore adding HbA1c to the iLFT algorithm for those with iL15 outcomes, to identify patients with possible new pre-diabetes or type 2 diabetes diagnoses, which are both significant risk factors for and complications of MASLD [42]. With the recent US Food and Drug Administration (FDA) approval of resmetirom for metabolic dysfunction-associated steatohepatitis (MASH), an inflammatory variant of MASLD with increased progression to cirrhosis, there is even greater importance in diagnosing MASLD [43]. At a health-service level, the improved diagnosis of MASLD could provide additional benefits such as more accurate disease coding and prevalence estimation, helping to inform health policy.…”

Section: Further Refining the Algorithmmentioning

confidence: 99%

Intelligent Liver Function Testing (iLFT): An Intelligent Laboratory Approach to Identifying Chronic Liver Disease

Nobes,

Leith,

Handjiev

et al. 2024

Diagnostics

View full text Add to dashboard Cite

The intelligent Liver Function Testing (iLFT) pathway is a novel, algorithm-based system which provides automated laboratory investigations and clinical feedback on abnormal liver function test (LFT) results from primary care. iLFT was introduced to NHS Tayside, Scotland, in August 2018 in response to vast numbers of abnormal LFTs, many of which were not appropriately investigated, coupled with rising mortality from chronic liver disease. Here, we outline the development and implementation of the iLFT pathway, considering the implications for the diagnostic laboratories, primary care services and specialist hepatology clinics. Additionally, we describe the utility, outcomes and evolution of iLFT, which was used over 11,000 times in its first three years alone. Finally, we will consider the future of iLFT and propose areas where similar ‘intelligent’ approaches could be used to add value to laboratory investigations.

show abstract

Section: Further Refining the Algorithmmentioning

confidence: 99%

Intelligent Liver Function Testing (iLFT): An Intelligent Laboratory Approach to Identifying Chronic Liver Disease

Nobes,

Leith,

Handjiev

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets

Qian,

Wang,

Chen

et al. 2024

Semin Liver Dis

View full text Add to dashboard Cite

Alcohol-related liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), two main types of steatotic liver disease (SLDs), are characterized by a wide spectrum of several different liver disorders, including simple steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma. Multiple immune cell-mediated inflammatory responses not only orchestrate the killing and removal of infected/damaged cells but also exacerbate the development of SLDs when excessive or persistent inflammation occurs. In recent years, single-cell and spatial transcriptome analyses have revealed the heterogeneity of liver-infiltrated immune cells in ALD and MASLD, revealing a new immunopathological picture of SLDs. In this review, we will emphasize the roles of several key immune cells in the pathogenesis of ALD and MASLD and discuss inflammation-based approaches for effective SLD intervention. In conclusion, the study of immunological mechanisms, especially highly specific immune cell population functions, may provide novel therapeutic opportunities for this life-threatening disease.

show abstract

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Puengel,

Tacke

2024

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Opportunities and challenges following approval of resmetirom for MASH liver disease

Cited by 4 publications

References 14 publications

Intelligent Liver Function Testing (iLFT): An Intelligent Laboratory Approach to Identifying Chronic Liver Disease

Intelligent Liver Function Testing (iLFT): An Intelligent Laboratory Approach to Identifying Chronic Liver Disease

Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Contact Info

Product

Resources

About